Global Depression Drugs Market 2015-2019

うつ病治療薬の世界市場2015-2019

◆タイトル:Global Depression Drugs Market 2015-2019
◆商品コード:IRTNTR6053
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2015年6月10日
◆ページ数:107
◆資料形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Five UserUSD3,500 ⇒換算¥385,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,500 ⇒換算¥495,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、うつ病治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、業界の構造分析、うつ病治療薬の世界市場規模及び予測、作用機序別分析、市場シェア、地域別分析、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

About depression drugs
According to the WHO, depression is a common mental disorder that contributes significantly to the global burden of disease. It affects people across communities worldwide. It is characterized by sadness, loss of interest or pleasure, feelings of guilt or low self-worth, disturbed sleep or appetite, feelings of tiredness, and poor concentration. Depression can be roughly categorized into six different types. An individual with severe depression can have suicidal thoughts and behaviors. According to a 2012 estimate by the WHO, about 3,000 suicides take place each day, resulting in more than a million deaths each year. Depression can be recurrent and can be severely debilitating. Patients with mild depression can be treated with medications, but in cases of moderate or severe depression, the patient needs both medication and professional psychotherapy in the form of counseling. According to a 2008 report by the WHO, depression affects men and women equally, but women are more likely to be affected by depression than men. According to the CDC, depression can lead to many adverse behaviors in an individual such as alcoholism, smoking, and sleep disturbance. According to the CDC factsheet, in the US, one in every 10 individuals is affected by depression. According to the NIMH in the US, major depressive disorder is one of the most debilitating disorders in the US and affects about 14.80 million adults aged 18 years and above.
Technavio’s analysts forecast the global depression drugs market to grow at a CAGR of 5.25% over the period 2014-2019.

[Covered in this report]
This report covers the present scenario and the growth prospects of the global depression drugs market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used for the treatment of depression. The global depression drugs market is segmented based on the mechanism of action of the drugs used to treat depression, as mentioned below:
• Tricyclic antidepressants
• Serotonin-norepinephrine reuptake inhibitors
• Selective serotonin reuptake inhibitors
• Monoamine oxidase inhibitors
• Others

Technavio’s report, Global Depression Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, EMEA, and APAC; it also covers the market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key regions]
• Americas
• APAC
• EMEA

[Key vendors]
• Actavis
• Bristol-Myers Squibb
• Eli Lilly
• GlaxoSmithKline
• Pfizer

[Other prominent vendors]
• Abbott Laboratories
• Addex Therapeutics
• Alkermes
• AstraZeneca
• Aurobindo Pharma
• Avanir Pharmaceuticals
• Cerecor
• Chugai Pharmaceutical
• Dart NeuroScience
• Dr. Reddy’s Laboratories
• Edgemont Pharmaceuticals
• E-Therapeutics
• Euthymics
• Evotec
• F. Hoffmann-La Roche
• Fabre Kramer
• Gedeon Richter
• H. Lundbeck
• Intra-Cellular Therapies
• Janssen Pharmaceuticals
• Lupin
• Luye Pharma
• MSI Methylation Sciences
• Naurex
• Neuralstem
• Novartis
• Opko Health
• Otsuka Pharmaceutical
• Pierre Fabre
• Shire
• SK Biopharmaceuticals
• Somerset Pharmaceuticals
• Sun Pharmaceutical
• Sunovion Pharmaceuticals
• Suven
• Takeda Pharmaceutical
• Teva Pharmaceutical
• Torrent Pharmaceuticals
• Valeant Pharmaceuticals

[Market driver]
• Rise in patient population
• For a full, detailed list, view our report

[Market challenge]
• Threat of expiry of patents
• For a full, detailed list, view our report

[Market trend]
• Growing public awareness
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

【資料の目次】

01. Executive Summary

02.List of Abbreviations

03.Scope of the Report
03.1 Market overview
03.2 Product offerings

04.Product Profiles
04.1.1 Celexa
04.1.2 Fetzima
04.1.3 Lexapro
04.1.4 Viibryd
04.1.5 Cymbalta
04.1.6 Prozac
04.1.7 Symbyax
04.1.8 Paxil
04.1.9 Wellbutrin
04.1.10 Abilify
04.1.11 Effexor
04.1.12 Pristiq
04.1.13 Zoloft

05.Market Research Methodology
05.1 Market Research Process
05.2 Research Methodology

06.Introduction

07.Disorder Overview
07.1 Types of depression
07.1.1 Major depressive disorder
07.1.2 Persistent depressive disorder
07.1.3 Psychotic depression
07.1.4 Postpartum depression
07.1.5 Seasonal affective disorder
07.1.6 Bipolar disorder
07.2 Etiology
07.3 Epidemiology
07.3.1 Bipolar disorder among adults
07.3.2 Dysthymic disorder among adults
07.3.3 Major depression among adults
07.3.4 Major depression among adolescents
07.4 Treatment and management
07.5 Economic burden

08.Market Landscape
08.1 Market overview
08.2 Market size and forecast
08.3 Depression drugs market in US 2014-2019
08.3.1 Market size and forecast
08.4 Five forces analysis

09.Market Segmentation by Mechanism of Action

10.Geographical Segmentation
10.1 Segmentation of global depression drugs market by geography 2014

11.Pipeline Portfolio
11.1 Key information on late-stage pipeline molecules
11.1.1 Brexpiprazole
11.1.2 ALKS 5461
11.1.3 Cariprazine
11.1.4 TGFK07AD

12.Buying Criteria

13.Market Growth Drivers

14.Drivers and their Impact

15.Market Challenges

16.Impact of Drivers and Challenges

17.Market Trends

18.Trends and their Impact

19.Vendor Landscape
19.1 Competitive scenario
19.1.1 Key news
19.1.2 Mergers and acquisitions
19.2 Market share analysis 2014
19.2.1 Competitive assessment of top drugs used for treating depression
19.2.2 Bristol-Myers Squibb
19.2.3 Eli Lilly
19.2.4 Pfizer
19.2.5 GlaxoSmithKline
19.2.6 Actavis
19.3 Other and future prominent vendors

20.Key Vendor Analysis
20.1 Actavis
20.1.1 Key Facts
20.1.2 Business Overview
20.1.3 Business Segmentation
20.1.4 Business Segmentation by Revenue 2012 and 2013
20.1.5 Geographical segmentation by Sales 2013
20.1.6 Business Strategy
20.1.7 Recent Developments
20.1.8 SWOT Analysis
20.2 Bristol-Myers Squibb
20.2.1 Key Facts
20.2.2 Business Overview
20.2.3 Key Product Offerings
20.2.4 Revenue by Geography
20.2.5 Business Strategy
20.2.6 Key Information
20.2.7 SWOT Analysis
20.3 Eli Lilly
20.3.1 Key Facts
20.3.2 Business Overview
20.3.3 Business Segmentation by Revenue
20.3.4 Sales by Geography
20.3.5 Business Strategy
20.3.6 Key Information
20.3.7 SWOT Analysis
20.4 GlaxoSmithKline
20.4.1 Key facts
20.4.2 Business overview
20.4.3 Business segmentation by revenue 2014
20.4.4 Business segmentation by revenue 2013 and 2014
20.4.5 Geographical segmentation by revenue 2014
20.4.6 Business strategy
20.4.7 Recent developments
20.4.8 SWOT analysis
20.5 Pfizer
20.5.1 Key facts
20.5.2 Business overview
20.5.3 Business segmentation by revenue 2014
20.5.4 Business segmentation by revenue 2013 and 2014
20.5.5 Geographical segmentation by revenue 2014
20.5.6 Business strategy
20.5.7 Key developments
20.5.8 SWOT analysis

21.Other Reports in this Series

[List of Exhibits]

Exhibit 1: Market Research Methodology
Exhibit 2: NIMH classification of depression
Exhibit 3: Prevalence data for major depressive disorder among adults in US (2012)
Exhibit 4: Prevalence data for dysthymic disorder among adults in US (2012)
Exhibit 5: 12-month prevalence data for major depressive disorder with severe impairment among adults in US (2012)
Exhibit 6: Prevalence data for major depressive disorder among adults in US (2012)
Exhibit 7: Prevalence data for major depression among adults in US (2012)
Exhibit 8: WHO guidelines for management of depression
Exhibit 9: Economic burden of depression in US
Exhibit 10: Segmentation of costs associated with depression
Exhibit 11: Snapshot of economic burden of depression in US
Exhibit 12: Global depression drugs market 2014-2019 ($ millions)
Exhibit 13: Depression drugs market in US 2014-2019 ($ millions)
Exhibit 14: Segmentation of global depression drugs market by mechanism of action
Exhibit 15: Segmentation of global depression drugs market by mechanism of action 2014
Exhibit 16: Segmentation of global depression drugs market by geography 2014
Exhibit 17: Depression drugs: pipeline portfolio
Exhibit 18: Vendor ranking 2014
Exhibit 19: YoY growth rate of major depression drugs 2010-2014 ($ millions)
Exhibit 20: Revenue comparison of top drugs used for treating depression in 2013 ($ millions)
Exhibit 21: YoY global revenue of Abilify 2010-2014 ($ millions)
Exhibit 22: YoY global revenue of Cymbalta 2010-2014 ($ millions)
Exhibit 23: YoY global revenue of Pristiq 2010-2014 ($ millions)
Exhibit 24: YoY global revenue of Zoloft 2010-2014 ($ millions)
Exhibit 25: YoY global revenue of Effexor 2010-2014 ($ millions)
Exhibit 26: YoY global revenue of Wellbutrin 2010-2013 ($ millions)
Exhibit 27: YoY revenue of Wellbutrin in US 2010-2013 ($ millions)
Exhibit 28: YoY global revenue of Paxil 2010-2014 ($ millions)
Exhibit 29: Actavis: Business Segmentation
Exhibit 30: Actavis: Business Segmentation by Revenue 2012 and 2013 ($ million)
Exhibit 31: Actavis: Geographical segmentation by Sales 2013
Exhibit 32: Bristol-Myers Squibb Co.: Key Product Offerings (Based on Therapeutic Areas)
Exhibit 33: Bristol-Myers Squibb Co.: Revenue by Geographical Segmentation 2013
Exhibit 34: Eli Lilly: Business Segmentation by Revenue 2013
Exhibit 35: Eli Lilly: Business Segmentation by Revenue 2012 and 2013 ($ million)
Exhibit 36: Eli Lilly: Sales by Geography 2013
Exhibit 37: GlaxoSmithKline: Business segmentation by revenue 2014
Exhibit 38: GlaxoSmithKline: Business segmentation by revenue 2013 and 2014 ($ billion)
Exhibit 39: GlaxoSmithKline: Geographical segmentation by revenue 2014
Exhibit 40: Pfizer: Business segmentation by revenue 2014
Exhibit 41: Pfizer: Business segmentation by revenue 2013 and 2014 ($ billion)
Exhibit 42: Pfizer: Geographical segmentation by revenue 2014



【掲載企業】

Actavis, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Pfizer, Abbott Laboratories, Addex Therapeutics, Alkermes, AstraZeneca, Aurobindo Pharma, Avanir Pharmaceuticals, Cerecor, Chugai Pharmaceutical, Dart NeuroScience, Dr. Reddy's Laboratories, Edgemont Pharmaceuticals, E-Therapeutics, Euthymics, Evotec, F. Hoffmann-La Roche, Fabre Kramer, Gedeon Richter, H. Lundbeck, Intra-Cellular Therapies, Janssen Pharmaceuticals, Lupin, Luye Pharma, MSI Methylation Sciences, Naurex, Neuralstem, Novartis, Opko Health, Otsuka Pharmaceutical, Pierre Fabre, Shire, SK Biopharmaceuticals, Somerset Pharmaceuticals, Sun Pharmaceutical, Sunovion Pharmaceuticals, Suven, Takeda Pharmaceutical, Teva Pharmaceutical, Torrent Pharmaceuticals, Valeant Pharmaceuticals

【資料のキーワード】

うつ病治療薬、三環系抗うつ薬、選択的セロトニン再取り込み阻害薬、MAO阻害薬、製薬、医薬品

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[うつ病治療薬の世界市場2015-2019] (Global Depression Drugs Market 2015-2019 / IRTNTR6053)販売に関する免責事項
[うつ病治療薬の世界市場2015-2019] (Global Depression Drugs Market 2015-2019 / IRTNTR6053)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆